cagrilintide-semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Cagrilintide Combined with Semaglutide: A

The patient is given a mild sedative and relaxes while the area to be treated is gently filled with a tumescent solution, which numbs it from the inside

gastric juicederived tissue regenerative peptide Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids) Formula / M.W.: C 62 H 98 N 16 O 22 , ~1419.55 g/mol CAS: 137525-51-0 Compound 2: TB-500 (Thymosin Beta-4 / T4) Class: -thymosin family

They also have an impact on NAMPT levels 6 , which fluctuate to meet cellular NAD+ demand

KPV: Limited clinical and preclinical evidence Mechanistic NF-B data Small clinical trials in IBD (oral) and atopic dermatitis (topical/oral) No published subcutaneous human data for systemic effects